NEPHROTOXICITY OF THE CANCER DRUG IFOSFAMIDE
NEPHROTOXICITY OF THE CANCER DRUG IFOSFAMIDE
批准号:
2666166
负责人:
MARIANNA J ZAMLAUSKI
金额:
$10.11万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-30 至 2002-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Adapted from the Investigator's Abstract) The long-term
objective of this proposal is to provide insight into possible mechanisms by
which the cancer drug ifosfamide causes kidney dysfunction. Ifosfamide is
used to treat solid tumors in both adults and children. A nephrotoxic side
effect of ifosfamide treament is the development of Fanconi syndrome. This
syndrome results in generalized dysfunction of proximal tubule cells and may
lead to renal failure. The ifosfamide metabolites chloroacetaldehyde and
4-hydroxyifosfamide have been implicated as possible causes of renal
toxicity in patients treated with ifosfamide. The mechanism by which these
ifosfamide metabolites induce kidney dysfunction is not understood. The
specific aims are: 1) to investigate whether oxidant stress is a possible
mechanisms by which chloroacetalydehyde causes Fanconi syndrome in the
isolated perfused rat kidney preparation; 2) to investigate whether energy
depletion is a possible mechanisms by which chloroacetaldehyde caused
Fanconi syndrome in the isolated perfused rat kidney preparation; and 3) to
investigate whether 4-hydroxyifosfamide causes Fanconi syndrome in the
isolated perfused rat kidney preparation and whether the dysfunction is due
to oxidant stress or energy depletion. Oxidant stress will be assessed by
determining changes in the ratio of reduced to oxidized glutathione and the
malondialdehyde content in the kidney. Energy depletion will be assessed by
determining the kidney ATP content. Results from the proposed research will
contribute to our understanding of the mechanism by which the cancer drug
ifosfamide caused renal injury. Such information could then lead to
treatments that may prevent the injury to the kidney.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金